Table 1.

Study calendar

Visits	Inclusion	Treatment period	follow-up
Visits	Max 2 months prior to RT day 1		M1 1 month after end of RT	Before progression		After progression
				Every 6 months during 2 years	Every 6 months until progression	Every 6 months until death
Inclusion/exclusion criteria	X
Signed consent form	X
Inclusion (max 2 months prior to RT)	X
FCH PET	X (a)					X (b)
Physical examination with PS	X	X (d)	X	X	X	X
Prior history, tumor characteristics	X
Blood Pressure	X	X (d)	X	X
Acute toxicity during ADT and RT (f)		X (d)	X
Late toxicity (f)				X
QLQ-C30 et QLQ-PR25	X		X	X
PSA	X		X (f)	X (f)	X (f)
Testosterone	X (g)		X	X	X
ADT (c) + RT		X

(a) maximum 3 months prior to initiation of ADT

(b) at progression

(c) 6 months treatment staring on RT day 1 or maximum 3 months prior to RT

(d) once per week during RT

(e) biochemical progression = PSA higher than inclusion PSA with 2 successive rises in the same laboratory

(f) NCI-CTCAE v4.0

(g) 28 days prior to ADT